Eudaimonia Partners’s BeOne Medicines Ltd ONC Stock Holding History

Eudaimonia Partners’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-19	Closed	-$7K	–	1414
2021 Q1	$7K	Buy	+19	New	+$6.29K	﹤0.01%	1267

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Eudaimonia Partners's ONC Position: Q2 2021 in Review

Eudaimonia Partners sold out of BeOne Medicines Ltd (ONC) in Q2 2021, closing a stake of 19 shares — an estimated $7K sold.

Eudaimonia Partners first reported a position in ONC in Q1 2021 and held it in 1 quarter. The position peaked at $7K in Q1 2021. 268 funds tracked by Wall St. Rank hold ONC as of Q2 2021.

Eudaimonia Partners reported no remaining BeOne Medicines Ltd position as of Q2 2021 after selling out during the quarter.
Eudaimonia Partners sold 19 BeOne Medicines Ltd shares in Q2 2021, an estimated $7K.
Eudaimonia Partners first reported a position in BeOne Medicines Ltd in Q1 2021 and held it in 1 quarter.
Eudaimonia Partners's BeOne Medicines Ltd position peaked at $7K in Q1 2021.
268 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.